Last updated on June 2016

A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma


Brief description of study

A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

Detailed Study Description

You are being asked to take part in this study because you have pancreatic cancer that was removed by surgery. You are eligible for this study because there was no visible cancer left behind and not more than 10 weeks have passed since your operation.

Patients were first randomized (assigned by chance) to receive either standard treatment with gemcitabine or gemcitabine and erlotinib. Erlotinib is a pill that may help treat cancers by blocking a gene that is important in cancer growth. The use of erlotinib to try to prevent the recurrence of pancreatic cancer after surgery was investigational. A goal of this study was to compare the effects, good and/or bad, of the drug erlotinib in combination with gemcitabine to gemcitabine alone for patients with pancreatic cancer that was removed by surgery to find out which is better.

Clinical Study Identifier: TX143788

Contact Investigators or Research Sites near you

Start Over

Pamela Treas

Baptist Health Clinical Research Center & Lexington Cardiac Research Foundation
Lexington, KY USA
  Connect »